Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys - PubMed (original) (raw)
. 2008 Jul;36(7):1341-56.
doi: 10.1124/dmd.107.018234. Epub 2008 Apr 17.
Donghui Cui, Wenying Li, Anthony Barros Jr, Vinod K Arora, Haiying Zhang, Lifei Wang, Donglu Zhang, James A Manning, Kan He, Anthony M Fletcher, Marc Ogan, Michael Lago, Samuel J Bonacorsi, W Griffith Humphreys, Ramaswamy A Iyer
Affiliations
- PMID: 18420785
- DOI: 10.1124/dmd.107.018234
Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys
Lisa J Christopher et al. Drug Metab Dispos. 2008 Jul.
Abstract
This study describes the in vitro metabolism of [(14)C]dasatinib in liver tissue incubations from rat, monkey, and human and the in vivo metabolism in rat and monkey. Across species, dasatinib underwent in vitro oxidative metabolism to form five primary oxidative metabolites. In addition to the primary metabolites, secondary metabolites formed from combinations of the oxidative pathways and conjugated metabolites of dasatinib and its oxidative metabolites were also observed in hepatocytes incubations. In in vivo studies in rats and monkeys, the majority of the radioactive dose was excreted in the bile and feces. In bile duct-cannulated monkeys after an i.v. dose, 13.7% of the radioactive dose was excreted in the feces through direct secretion. Dasatinib comprised 56 and 26% of the area under the curve (AUC) (0-8 h) of total radioactivity (TRA) in plasma, whereas multiple metabolites accounted for the remaining 44 and 74% of the AUC (0-8 h) of TRA for rats and monkeys, respectively. In rat and monkey bile, dasatinib accounted for < 12% of the excreted dose, suggesting that dasatinib was extensively metabolized before elimination. The metabolic profiles in bile were similar to the hepatocyte profiles. In both species, a large portion of the radioactivity excreted in bile (> or = 29% of the dose) was attributed to N-oxides and conjugated metabolites. In rat and monkey feces, only the oxidative metabolites and their further oxidation products were identified. The absence of conjugative or N-oxide metabolites in the feces suggests hydrolysis or reduction, respectively, in the gastrointestinal tract before elimination.
Similar articles
- Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV, Wang J, Lee FY, Marathe PH. Kamath AV, et al. Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. doi: 10.1007/s00280-007-0478-8. Epub 2007 Apr 11. Cancer Chemother Pharmacol. 2008. PMID: 17429625 - Metabolism and disposition of dasatinib after oral administration to humans.
Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA. Christopher LJ, et al. Drug Metab Dispos. 2008 Jul;36(7):1357-64. doi: 10.1124/dmd.107.018267. Epub 2008 Apr 17. Drug Metab Dispos. 2008. PMID: 18420784 - Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.
He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ. He K, et al. Drug Metab Dispos. 2008 Dec;36(12):2564-70. doi: 10.1124/dmd.108.022764. Epub 2008 Sep 11. Drug Metab Dispos. 2008. PMID: 18787054 - The ADME profile of the fungicide tricyclazole in rodent via the oral route: A critical review for human health safety assessment.
Corvaro M, Bartels M. Corvaro M, et al. Regul Toxicol Pharmacol. 2019 Nov;108:104438. doi: 10.1016/j.yrtph.2019.104438. Epub 2019 Aug 25. Regul Toxicol Pharmacol. 2019. PMID: 31461669 Review.
Cited by
- Direct Carbon Isotope Exchange through Decarboxylative Carboxylation.
Kingston C, Wallace MA, Allentoff AJ, deGruyter JN, Chen JS, Gong SX, Bonacorsi S Jr, Baran PS. Kingston C, et al. J Am Chem Soc. 2019 Jan 16;141(2):774-779. doi: 10.1021/jacs.8b12035. Epub 2019 Jan 3. J Am Chem Soc. 2019. PMID: 30605319 Free PMC article. - Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.
Li X, He Y, Ruiz CH, Koenig M, Cameron MD, Vojkovsky T. Li X, et al. Drug Metab Dispos. 2009 Jun;37(6):1242-50. doi: 10.1124/dmd.108.025932. Epub 2009 Mar 12. Drug Metab Dispos. 2009. PMID: 19282395 Free PMC article. - Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Haura EB, et al. J Clin Oncol. 2010 Mar 10;28(8):1387-94. doi: 10.1200/JCO.2009.25.4029. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142592 Free PMC article. Clinical Trial. - Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.
Furmanski BD, Hu S, Fujita KI, Li L, Gibson AA, Janke LJ, Williams RT, Schuetz JD, Sparreboom A, Baker SD. Furmanski BD, et al. Clin Cancer Res. 2013 Aug 15;19(16):4359-4370. doi: 10.1158/1078-0432.CCR-13-0980. Epub 2013 Jun 21. Clin Cancer Res. 2013. PMID: 23794731 Free PMC article. - A simple model predicts UGT-mediated metabolism.
Dang NL, Hughes TB, Krishnamurthy V, Swamidass SJ. Dang NL, et al. Bioinformatics. 2016 Oct 15;32(20):3183-3189. doi: 10.1093/bioinformatics/btw350. Epub 2016 Jun 20. Bioinformatics. 2016. PMID: 27324196 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources